Shots:
- The P-III CheckMate -648 trial involves assessing Opdivo (nivolumab) + CT or Opdivo (3 mg/kg, q2w) + Yervoy (1 mg/kg, q6w up to 24mos.) in patients with unresectable advanced or metastatic ESCC
- Results: Both the combinations demonstrated OS benefits in PD-L1 positive and all-randomized populations
- Additionally, Opdivo + CT met its 1EP of PFS while Opdivo + Yervoy failed to meet its 1EPs of PFS. The safety profiles of Opdivo and the combination of Opdivo and Yervoy were consistent with previously reported studies
Click here to read full press release/ article | Ref: BMS | Image: BMS
The post BMS Reports Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or Metastatic ESCC first appeared on PharmaShots.
